Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | acetylcholinesterase | 0.0215 | 0.4593 | 0.402 |
Echinococcus granulosus | plexin a4 | 0.0351 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0173 | 0.2901 | 0.2147 |
Brugia malayi | Carboxylesterase family protein | 0.0215 | 0.4593 | 0.402 |
Schistosoma mansoni | hypothetical protein | 0.0173 | 0.2901 | 0.2203 |
Trypanosoma brucei | RNA helicase, putative | 0.0345 | 0.977 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.0215 | 0.4593 | 0.402 |
Onchocerca volvulus | 0.0297 | 0.7837 | 1 | |
Echinococcus granulosus | acetylcholinesterase | 0.0215 | 0.4593 | 0.402 |
Loa Loa (eye worm) | carboxylesterase | 0.0215 | 0.4593 | 0.402 |
Schistosoma mansoni | hypothetical protein | 0.0345 | 0.977 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0215 | 0.4593 | 0.402 |
Loa Loa (eye worm) | hypothetical protein | 0.0215 | 0.4593 | 0.402 |
Schistosoma mansoni | plexin | 0.0297 | 0.7837 | 0.7806 |
Loa Loa (eye worm) | hypothetical protein | 0.0297 | 0.7837 | 0.7608 |
Loa Loa (eye worm) | hypothetical protein | 0.0215 | 0.4593 | 0.402 |
Schistosoma mansoni | plexin | 0.0173 | 0.2901 | 0.2203 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0215 | 0.4593 | 0.402 |
Brugia malayi | Plexin repeat family protein | 0.0297 | 0.7837 | 0.7608 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0215 | 0.4593 | 0.402 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0215 | 0.4593 | 0.4125 |
Echinococcus granulosus | carboxylesterase 5A | 0.0215 | 0.4593 | 0.402 |
Echinococcus multilocularis | acetylcholinesterase | 0.0215 | 0.4593 | 0.402 |
Echinococcus multilocularis | plexin a4 | 0.0351 | 1 | 1 |
Loa Loa (eye worm) | plexin A | 0.0351 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.